Antisense Oligonucleotides Against VR1

a technology of anti-vr1 and oligonucleotides, which is applied in the field of anti-vr1 anti-oligodeoxynucleotides, can solve the problems of increasing the number of side effects of existing analgesics, and increasing the number of receptors per cell. , to achieve the effect of preventing the development of hyperalgesia and allodynia and reducing the number of receptors per cell

Inactive Publication Date: 2010-12-16
GRUNENTHAL GMBH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The effective treatment of pain is a major challenge to molecular medicine.
Unfortunately, pharmacological treatment of chronic pain is still unsatisfactory and thus remains a challenge to current medical research.
Currently existing analgesics often have an inadequate action and sometimes have severe side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antisense Oligonucleotides Against VR1
  • Antisense Oligonucleotides Against VR1
  • Antisense Oligonucleotides Against VR1

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of Generally Suitable Restriction Sites

[0106]The first step in the antisense and ribozyme strategy is to identify accessible sites on the mRNA for binding oligonucleotides, in particular ribozymes. To this end, the VR1 mRNA had to be investigated for such restriction sites. Analysis of the VR1 mRNA revealed the following potential recognition sites for ribozymes in the coding domain:

[0107]33×GT(U)C sequences,

[0108]28×GT(U)T sequences, and

[0109]12×GT(U)A sequences.

[0110]In order to determine the accessible sites on the VR1 mRNA, in a first step, three independent nucleotide mixtures with the following sequence were synthesized:[0111]Mixture 1: NNNAACNNN “GUU library,”[0112]Mixture 2: NNNCACNNN “GUA library,” and[0113]Mixture 3: NNNGACNNN “GUC library.”

[0114]These were used consecutively in an RNase H experiment and it was found that appreciable degradation of the VR1 mRNA was observed only with the GUC library. Thus, of the potential target sequences for ribozymes, the...

example 2

Identification of the Most Effective Antisense Oligodeoxynucleotides

[0115]Messenger Walk Screening

[0116]In order to identify mRNA domains which are accessible to antisense oligodeoxynucleotides, the mRNA was systematically screened with ODNs in an RNase H assay (messenger walk screening). The ODNs were 18 nucleotides in length and contained a central GAC sequence, which is reverse complementary to GUC sequences in the mRNA. This triplet was selected as the target as it provided good results and may be used in a second step to develop hammerhead ribozymes and DNA enzymes. In total, 33 ODNs, designated V1 to V33, were tested against all the GUC sites of the VR1 mRNA. The ODNs were systematically screened for their suitability by the addition in each case of one ODN and RNase H to the mRNA. RNase H cuts formed DNA / RNA duplexes wherever an oligonucleotide can bind to the mRNA (FIG. 17).

[0117]In Vitro Transcription of VR1 mRNA

[0118]First of all, the cDNA of the vanilloid receptor was clo...

example 3

Ribozymes and DNA Enzymes

[0129]On the basis of the identified most effective binding sites, corresponding ribozymes and DNA enzymes were also investigated.

[0130]“Hammerhead” ribozymes and type “10-23” DNA enzymes (Santoro et al., 1997) were constructed against the mRNA sites which were accessible to ODNs. The length of the “recognition arms” was 7 or 9 nucleotides on each side. Quantitative evaluation of mRNA cleavage / restriction under “single turnover” conditions (10-fold excess of ribozymes and DNA enzymes) revealed after 20 minutes at 37° C. that ribozymes with shorter “recognition arms” (helix I and helix III) are more active, while in turn in DNA enzymes, those with longer “arms” (Fragment I and Fragment III) are more active (FIG. 20). FIG. 24 is a schematic representation of a ribozyme with the helices I and III, while FIG. 25 shows a specific example. This may be seen for a 10-23 DNA enzyme (5′-end (Fragment I) and 3′-end (Fragment III) from the catalytic motif) in Santoro et...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application is a division of application Ser. No. 10 / 376,341, filed Mar. 3, 2003, now U.S. patent Ser. No. ______, which in turn is a continuation of International Patent Application No. PCT / EP01 / 10081, filed Aug. 31, 2001, designating the United States of America and published in German as WO 02 / 18407 A2, the entire disclosure of which is incorporated herein by reference. Priority is claimed based on Federal Republic of Germany Patent Application Nos. 100 43 674.9, filed Sep. 2, 2000, and 100 43 702.8, filed Sep. 4, 2000.BACKGROUND AND SUMMARY OF THE INVENTION[0002]The invention relates to antisense oligodeoxynucleotides against VR1, to corresponding nucleotide constructs, to cells, pharmaceutical preparations and diagnostic preparations containing these, to the use thereof in pain therapy and to methods for diagnosing symptoms associated with VR1 and for identifying pain-modulating substances.[0003]The effective treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C07H21/04C07H21/02A61P29/00A61P35/00A61P13/06A61P17/04G01N33/566G01N33/50A61K31/7088A61K31/7115A61K31/712A61K31/7125A61K38/00A61P13/00A61P17/00A61P25/02C12N1/15C12N1/19C12N1/21C12N5/10C12N15/09C12N15/113C12Q1/02C12Q1/68G01N33/15G01N33/53
CPCA61K38/00A61K48/00C12N15/1138C12N2310/12C12N2310/121C12N2310/315C12N2310/3231A61P13/00A61P13/06A61P17/00A61P17/04A61P25/02A61P29/00A61P35/00
Inventor KURRECK, JENSERDMANN, VOLKER A.
Owner GRUNENTHAL GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap